Solid Tumor Center

LIke ThisLIke ThisLIke ThisLIke ThisLIke This

Solid tumors represent a wide variety of pediatric cancers. Some of the more prevalent forms of these cancers are neuroblastoma, osteosarcoma, Ewing sarcoma, Wilms tumor, rhabdomyosarcoma, retinoblastoma, and liver and germ cell tumors. Patients generally require a combination of treatments that may include surgical removal of the tumor, chemotherapy and radiation therapy.

Children with solid tumors are treated through the Solid Tumor Center at Dana-Farber/Boston Children's Cancer and Blood Disorders Center, an integrated pediatric hematology and oncology partnership between Dana-Farber Cancer Institute and Boston Children's Hospital. Our doctors provide unparalleled expertise in the diagnosis, treatment and management of these diseases. Dana-Farber/Boston Children’s was one of the first centers in the United States to use adjuvant chemotherapy and perform limb salvage surgery for patients with osteosarcoma. The team continues to advance the treatment of pediatric solid tumors by offering unique therapies, such as radioiodine-labeled metaiodobenzylguanidine (I-131 MIBG) treatment for neuroblastoma.

Our multidisciplinary approach to care ensures in-depth discussion of each case and personalized treatment plans for every patient. We integrate expertise from the following specialists: 

  • pediatric oncologists, surgical oncologists, radiation oncologists and stem cell transplant physicians
  • pediatric experts from every medical subspecialty, such as orthopedics, endocrinology, ophthalmology, interventional radiology, nephrology (kidney), hepatology (liver) and radiology, among others
  • highly skilled and experienced pediatric oncology nurses
  • child life specialists, psychologists, social workers and resource specialists who provide supportive care before, during and after treatment

Learn more about the the Solid Tumor Center Dana-Farber/Boston Children's Cancer and Blood Disorders Center.

The future of pediatrics will be forged by thinking differently, breaking paradigms and joining together in a shared vision of tackling the toughest challenges before us.”
- Sandra L. Fenwick, President and CEO
Close